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1. Introduction
Tumor suppressor genes (TSGs) function in concert with diverse parts of the cellular machi‐
nery and integrate the signaling networks in a cell [1]. TSGs act to safeguard the networks,
to fine-tune signaling outputs, and to maintain tissue homeostasis. The loss of tumor sup‐
pressor activity or inactivation of a TSG is often due to genetic alterations such as a loss-of-
function mutation or a deletion in the gene; alternatively, epigenetic silencing can result
from methylation or histone modification in the TSG’s promoter regulatory elements [1-3].
Cells with a loss or a significant reduction of a particular tumor suppressor’s activity are
prone to develop neoplasia in the tissues/organs where the TSG is expressed [1, 2].
The properties and modes of action of TSGs can be very distinct from one class to another.
Most TSGs encode proteins that participate in controlling cell cycle progression, inducing
apoptosis, repairing damaged DNAs, or performing other important functions [1]. TSGs can
also be a source of microRNAs, a class of small hairpin RNAs that are transcribed in many
cells and may act as tumor suppressors by regulating the expression of their targeted genes
[4]. In this chapter, we will focus on one class of the TSGs, represented by the mitogen-indu‐
cible gene 6 (MIG-6) and Sprouty 2 (SPRY2), whose activities are crucial in regulating recep‐
tor tyrosine kinases signaling through negative feedback loops.
Receptor tyrosine kinases (RTKs) are important cellular components, and there are nearly 60
members encoded in the genome [5, 6]. They all possess a single transmembrane domain
linking their extracellular ligand-binding region to the cytoplasmic region in which the cata‐
lytic kinase domain and the domain for docking of downstream signaling molecules reside.
Upon binding of the ligand to its physiologic RTK partner, the receptors dimerize, resulting
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in autophosphorylation of key tyrosine residues in the kinase domain. This leads to a con‐
formational change in the receptor and the recruitment of downstream signaling molecules
to its docking domain or in close proximity for phosphorylation and activation. In this cellu‐
lar process, the RTK plays a central role by relaying external stimuli (ligands) to internal sig‐
naling cascades such as the RAS-MAPK or PI3K-AKT pathways, translating the signal input
into biological actions ranging from mitogenesis, to motility, morphogenesis, metabolism,
and many others [5, 6].
RTK signaling is essential in many developmental processes and in normal physiology, and
the actions of RTKs must be controlled temporally and spatially [5, 6]. Their actions are
tightly regulated at several molecular levels to ensure appropriate cellular responses.
Among the mechanisms that keep RTK signaling in “check and balance” are receptor endo‐
cytosis/degradation, dephosphorylation by protein tyrosine phosphatases (PTPs), and nega‐
tive feedback regulation. Signal overactivity caused by inappropriate RTK activation can
lead to serious pathological outcomes, particularly cancer. Thus, many RTKs such as epider‐
mal growth factor receptor (EGFR) and the N-methyl-N’-nitroso-guanidine human osteosar‐
coma (MNNG HOS) transforming gene (MET) have been classified as oncogenes, because
activating mutations, amplifications or other anomalies in these receptors have been identi‐
fied in various human cancers, and their roles in the development and progression of tumor
malignancy have been well documented [7, 8]. For example, aberrant activation of MET can
result in deregulated cell proliferation, transformation, and promotion of tumor cell inva‐
sion and metastasis [8].
Unlike the rapid attenuation resulting from receptor endocytosis/degradation or PTP-medi‐
ated dephosphorylation, negative feedback regulation of RTK signaling by MIG-6 and
SPRY2 is a delayed event because it requires de novo mRNA and protein syntheses. The ex‐
pression of both MIG-6 and SPRY2 can be induced by ligands of many RTKs including epi‐
dermal growth factor (EGF), hepatocyte growth factor (HGF), and fibroblast growth factor
(FGF) [9, 10]. In turn, MIG-6 and SPRY2 exerts their inhibitory activities on RTK signaling by
either directly affecting the receptor itself or by modulating the signaling molecules down‐
stream of the RTK. In this review, we will highlight the current understanding of how
MIG-6 and SPRY2 regulates RTK signaling via negative feedback loops, and shed lights on
why the loss of their tumor suppressor activities may affect RTK signaling in cancer cells, as
well as their impact on cancer therapy.
2. The features and functions of MIG-6 and SPRY2
2.1. MIG-6
MIG-6  (also  known  as  gene  33,  ERRFI1  or  RALT)  is  a  unique  and  immediate  early  re‐
sponse gene that is not present in relatively simple organisms like Drosophila  and C. ele‐
gans.  It  emerges  in  the  more  complex,  higher-order  species  [9,  11],  underlying  its
importance in evolution. It  encodes a 58 kDa nonkinase protein that resides in the cyto‐
plasm and functions as  a  scaffolding adaptor for  modulating signal  transduction.  Struc‐
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turally, MIG-6 has several functional motifs/domains that are crucial for interaction with
other signaling molecules [9,  12].  The Cdc42/Rac-interaction and binding (CRIB) domain
of MIG-6 (Figure 1A) shares consensus sequences with many other proteins that associate
with Cdc42 or  Rac small  GTPases,  which are important  regulators  of  actin cytoskeleton
remodeling and signal transduction [11, 13]. CRIB domain mediates the binding of MIG-6
to  active  (GTP-bound)  Cdc42  and  negatively  regulates  HGF-induced  Cdc42  activation
and cell migration [12, 14]. This domain has also been shown to play a role in regulating
transactivation of  nuclear  factor  κB (NFκB)  by  sequestering the  inhibitor  of  κBα (IκBα)
[15, 16]. Within its middle region, MIG-6 has several proline-rich motifs that likely medi‐
ate  its  binding  to  various  Src  homology-3  (SH3]  domain-containing  proteins  such  as
GRB2, Src, PI3K p85 and PLC-γ [14, 17]. MIG-6 interacts with 14-3-3ζ via the 14-3-3 pro‐
tein  binding  motif  [12].  MIG-6  also  possesses  two  PEST  sequences,  and  is  targeted  by
ubiquitination and proteasome degradation [18].  The ErbB-binding region (EBR),  a large
portion of the carboxyl terminus in MIG-6, is required for physical interaction with EGFR
family receptors, which resulted in attenuation of EGFR/ErbBs signaling [17, 19, 20]. The
EBR  domain  shares  a  high  homology  with  the  activated  Cdc42-associated  kinase  1
(ACK1), a non-receptor tyrosine kinase that also interacts with and regulates EGFR [21].
Figure 1. MIG-6 and SPRY2 structures. A. MIG-6 protein structural features and its interacting partners. The CRIB do‐
main (amino acids 1-38) interacts with Cdc42 and IκBα. The orange box indicates the SH3-domain binding motif that
likely mediates interactions with SH3-domain-containing proteins such as GRB2 and PI3Kp85. The cyan box (amino
acids 246-253) marks the 14-3-3 binding motif in which serine residue 251 can be phosphorylated by Chk1 kinase. The
EBR domain (amino acids 337-412) binds to EGFR and other ErbB members. The red bar (ED) indicates the MIG-6 en‐
docytic domain (amino acids 143-323); the blue bar indicates the Ack homology (AH) region (amino acids 264-424). B.
Structural features of SPRY2 and its partner molecules. The red box shows the SH2-domain binding motif (amino acids
50-60) that binds to CBL and GRB2; the key tyrosine residue Y55 is also indicated. The conserved cysteine-rich SPRY
domain (amino acids 178-293) is crucial for its ability to interact with signaling molecules such as FRS2 and SHP2. The
SPRY domain is also responsible for membrane translocation (MTD). There is an SH3-domain binding motif (amino
acids 303-309) shown in blue at the C-terminal end of SPRY2 that also binds to GRB2.
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MIG-6 is expressed in many tissues/organs, with high expression in liver and kidney and
low to moderate expression in brain, lung, heart, and other tissues [22, 23]. Its expression
can be induced by diverse factors ranging from hormones and growth factors, to chemical
agents, to stress stimuli [9]. The induction of MIG-6 expression by growth factors is mainly
mediated by the RAS-MEK-MAPK/ERK pathway, while other inducers may involve other
pathways such as PI3K [9]. MIG-6 has also been reported to be a G-actin-regulated target
gene, because the actin-MAL-serum response factor (SRF) cascade mediates MIG-6 induc‐
tion by serum or lipid agonists such as lysophosphatidic acid (LPA) or sphingosine 1-phos‐
phate (S1P) [24]. MIG-6 may play a crucial role in patho-physiological conditions such as
myocardial ischemic injury and infarction [25], liver regeneration [26-28], joint mechanical
injury [29], and diabetic nephropathy and hypertension [12]. Its activity is required for skin
morphogenesis [30, 31] and lung development in mice [32], and it plays an important role in
the maintenance of tissue homeostasis in joints, the lungs and the uterus [32-35].
2.2. SPRY2
In term of evolution, the Spry gene emerged far earlier than Mig-6. SPRY2 is the mammalian
homolog of Drosophila melanogaster Spry (dSpry), and is one of the four SPRY genes in the
human genome [10]. The dSpry protein is 63 kDa, while its mammalian counterparts are 32–
34 kDa, but they all contain a functional cysteine-rich region in their C-terminus (designated
the SPRY domain) and an SH2-binding motif carrying a conserved tyrosine at the N-termi‐
nus (Tyr55 residue in human SPRY2) (Figure 1B). These conserved regions are essential for
SPRY2 to fully execute its inhibitory function in the regulation of RTK signaling [10, 36, 37].
The SPRY domain is also found in the SPRED (Sprouty-related EVH1 domain-containing
protein) family, which like SPRY proteins inhibits RTK signaling upon stimulation by
growth factors [10, 38]. The SPRY domain mediates the binding of SPRY2 to many signaling
molecules including GAP1, FRS2, SHP2, RAF, PKCδ, TESK1 and caveolin1 [10, 39]. The
SPRY domain is also required for translocation of SPRY2 to the membrane during its activa‐
tion. The Tyr55 residue is essential for the SPRY2 protein’s interaction with CBL, PP2A and
GRB2 [10, 39]. A cryptic SH3-binding motif (PxxPxR) in the C-terminal end of SPRY2 (but
not present in other SPRY members) has been shown to mediate GRB2 interaction as well
[39-41]. The dual-specificity tyrosine phosphorylation–regulated kinase (DYRK1A) interacts
with and phosphorylates Thr75 on SPRY2 [42]. SPRY2 is targeted for ubiquitination and
proteasome degradation by at least two ubiquitin E3 ligases: CBL-mediated Tyr55 phos‐
phorylation-dependent ubiquitination and SIAH2-mediated Tyr55 phosphorylation-inde‐
pendent ubiquitination [43, 44]. On the other hand, SPRY2 protein can be stabilized by
phosphorylation of its serines 112 and 121 residues by the mitogen-activated protein kinase-
interacting kinase 1 (Mnk1], thereby decreasing growth factor–induced degradation [45].
In Drosophila, dSpry expression is detected at the tips of branching lung buds and is induced
by branchless, the Drosophila Fgf. Losing dSpry leads to excessive tracheal branching as a re‐
sult of increased Fgf signaling activity [46]. The Xenopus homolog, xSpry2, is expressed in a
pattern resembling that of Xenopus Fgf8 and inhibits Fgf-mediated gastrulation [47]. During
mammalian embryogenesis, Spry2 expression tends to localize closest to the sites where Fgf
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activity is needed for organ/tissue development, underlying the importance of this molecule
as an intrinsic Fgf signaling regulator in organogenesis [48-50]. Mouse Spry2 is highly ex‐
pressed in the terminal buds of peripheral mesenchyme in the embryonic lung, adjacent to
that of Fgf10, a key mouse lung-branching morphogen [50]. Ectopic expression of Spry2 in
the mouse pulmonary epithelium results in decreased branching; exogenous Fgf10 produces
greater lung branching and higher Spry2 expression [50]. Spry2 also plays a role in mouse
kidney development; its ectopic expression in the ureteric bud leads to postnatal kidney fail‐
ure due to deficiency in ureteric branching [51]. Moreover, Spry2 deficiency in mice results
in defects of the auditory sensory epithelium development in the inner ear, and leads to en‐
teric neuronal hyperplasia and esophageal achalasia [52, 53]. The lack of phenotypes in oth‐
er Spry2-deficient tissues is likely due to compensatory roles of other Spry family members,
because there are overlapping expressions of Spry1, 2 and 4 in many tissues during the de‐
velopment [54]. In adult mice, Spry2 expression is abundant in the brain, lung, heart, kid‐
ney, skeletal muscle and mammary glands [48, 55].
Beyond being an intrinsic inhibitor for Fgf signaling, Spry also regulates signaling driven by
other RTKs like Egfr. The dSpry gene is required for eye and wing development in Drosophi‐
la, antagonizing Egfr signaling for neuronal induction in the retina and for vein formation in
the wings [56, 57]. Loss of dSpry results in excess photoreceptors, cone cells and pigment
cells in the retina, while its overexpression leads to phenotypes that mimic loss of Egfr sig‐
naling [56, 57].
3. Negative feedback regulation of RTK signaling by MIG-6 and SPRY2
3.1. Regulation of RTK pathways by MIG-6
Many growth factors can induce MIG-6 expression, including EGF, FGF, and HGF [9]. Upon
induction, MIG-6 proteins rapidly and transiently accumulate in the cytoplasm, where they
feed back to inhibit the activated RTK signaling (Figure 2]. The inhibition of EGFR/ErbB sig‐
naling by MIG-6 can occur at two molecular levels: one on the receptor itself, and another on
the signaling molecules downstream of the receptor (Figure 2). Through its C-terminal EBR
domain, MIG-6 directly binds to EGFR and other ErbB members [17, 19, 20, 58]. The interac‐
tion involves the kinase domain of EGFR or ErbB2 and requires their catalytic activities, but
does not involve their C-terminal regions in which there are tyrosine residues essential for
activating downstream signaling [20, 58]. Crystal structures reveal that the MIG-6 EBR do‐
main binds to the distal surface of the carboxy-terminal lobe (C-lobe) in the kinase domain
of EGFR [59]. The C-lobe is crucial in asymmetric EGFR dimer formation [60]; binding of
MIG-6 to the C-lobe blocks the dimer interface thereby preventing EGFR activation [59].
MIG-6 coupling also promotes clathrin-mediated endocytosis of EGFR [61], an important
mechanism for timely attenuation of ligand-induced EGFR activation [62, 63]. The region re‐
sponsible for promoting EGFR endocytosis has been mapped to the endocytic domain (ED)
of MIG-6 (see Figure 1A) [61], which mediates the binding of MIG-6 to the AP2 adaptor
complex, a key component in forming clathrin-coated pits during endocytosis [63]. Interest‐
MIG-6 and SPRY2 in the Regulation of Receptor Tyrosine Kinase Signaling: Balancing Act via Negative Feedback Loops
http://dx.doi.org/10.5772/54393
203
ingly, the non-receptor tyrosine kinase ACK1 also binds to EGFR upon EGF stimulation
through a region sharing high homology with the MIG-6 EBR domain [21]. This interaction
also regulates clathrin-mediated EGFR endocytosis and degradation [21, 64]. However, it is
not clear whether MIG-6 and ACK1 cooperate in regulating EGFR turnover or whether they
bind to EGFR in a mutually exclusive way to accomplish individual inhibitory roles under
different circumstances. The internalized EGFR is guided to late endosome through the
binding of MIG-6 to the endosomal SNARE complex component STX8, en route to degrada‐
tion in the lysosome [61, 65].
Figure 2. MIG-6 regulates EGFR and MET signaling via a negative feedback loop. Upon ligand stimulation, EGFR and
MET activate the RAS-RAF-MEK-ERK pathway and induce MIG-6 expression. In turn, MIG-6 exerts its inhibitory activity
by interacting with signaling molecules to fine-tune RTK signaling and its timely attenuation. The direct MIG-6–EGFR
interaction facilitates receptor endocytosis and degradation. This inhibitory activity is unique to the EGFR family and
does not extend to other RTKs like MET. The interaction of MIG-6 with signaling molecules such as GRB2 and PI3Kp85
indistinguishably influences the RTK signaling in general, resulting in the inhibition of downstream pathways like RAS-
MAPK/ERK and PI3K-AKT.
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The magnitude of MIG-6-mediated inhibition of EGFR signaling is likely maximized and in‐
tegrated by the second level of molecular regulation, that is, direct inhibition of downstream
signaling molecules (Figure 2). MIG-6 binds to the SH3 domain-containing protein GRB2
[14, 17], the key molecule in linking activated RTK to the intracellular signaling cascade;
GRB2 brings RAS together with SOS to the phosphorylated receptor for activation [66].
Binding of MIG-6 may block GRB2’s interaction with activated EGFR and other RTKs or dis‐
rupt GRB2-SOS-RAS complex formation, thereby preventing activation of the RAS-MEK-
MAPK pathway. MIG-6 also interacts with Src, the PI3K p85 subunit, PLCγ, and Fyn [17],
although those interactions were demonstrated in an artificial system and their biological
meaning remains to be determined. More complexity is likely in the dynamics of MIG-6-
mediated RTK signaling regulation due to the interaction of MIG-6 with 14-3-3 proteins [12,
67], an adaptor family that may interact with diverse signaling molecules and regulate many
biological activities [68]. Nonetheless, most of these direct downstream signaling regulations
by MIG-6 remain largely speculation and require further investigation.
Assessing  the  effect  of  MIG-6  on  RTK pathways  other  than  those  of  the  EGFR family,
however,  may provide insightful  answers to  such speculation,  because direct  regulation
of  the  RTK  itself  by  MIG-6  appears  to  be  unique  to  the  EGFR  family.  For  instance,
MIG-6 can be induced by HGF and function as negative feedback regulator of the MET
pathway by inhibiting HGF-induced cell migration and proliferation [14], yet no physical
interaction  between  MIG-6  and  MET  has  been  observed.  Through  its  CRIB  domain,
MIG-6 can bind to and inhibit  the activity of the Cdc42 small  GTPase [12,  14],  and this
inhibitory activity is required for blocking of HGF-induced cell migration [14]. The CRIB
domain  also  interacts  with  IκBα,  thereby  activating  NFκB for  transcriptional  regulation
of its target gene expression [15, 16].  Whether the inhibition of HGF-induced cell  prolif‐
eration by MIG-6 is  mediated by its  ability to bind GRB2 or to bind other downstream
molecules  is  still  unknown.  Negative  feedback  inhibition  of  other  RTKs  (such  as  FGFR
and  IGFR)  by  MIG-6  is  also  likely  to  be  mediated  by  its  inhibitory  activities  on  the
downstream signaling molecules rather than on the receptor itself.
The inhibitory activity of MIG-6 on RTK signaling seems to be modulated by phosphoryla‐
tion; Liu et al. recently reported that MIG-6 can be phosphorylated by Chk1 upon EGF stim‐
ulation [67]. EGF activates Chk1 via the PI3K-AKT-S6K pathway, which in turn
phosphorylates Ser251 of MIG-6 and results in inhibition of MIG-6 [67]. Thus, Chk1 counter-
balances the EGFR inhibition of MIG-6, positively regulating EGFR signaling. Interestingly,
Ser251 resides in the 14-3-3 binding motif of MIG-6 and its phosphorylation is likely in‐
volved in the MIG-6 and 14-3-3ζ interaction, because that interaction is abolished by Chk1
depletion [67]. In addition, two tyrosine residues (Tyr394 and Tyr458) in MIG-6 are phos‐
phorylated by EGFR activation [69-71], but the underlying mechanism and the biological
significance remain unclear.
3.2. Regulation of RTK pathways by SPRY2
SPRY2 renders another layer of modulation on RTK signaling via a negative feedback loop
[10, 36, 37, 72]; its expression is induced by many activated RTKs including EGFR, FGFR,
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MET, and VEGFR [10, 72]. As with MIG-6, SPRY2-mediated regulation can occur on two
levels: on the RTK itself and on the downstream signaling molecules (Figure 3). However
unlike MIG-6, the most prominent inhibitory activity of SPRY2 is derived from its abilities to
interact with downstream signaling molecules centering on the RAS-RAF-MAPK pathway,
while its effect on the RTK itself seems to be indirect and may provide some signaling spe‐
cificity for different RTKs [10, 36, 37].
Figure 3. Feedback regulation of EGFR and FGFR signaling by SPRY2. SPRY2, upon induction, translocates to the mem‐
brane by binding to PtdIns(4,5)P2, and is phosphorylated on its Y55 residue. This modification is essential for SPRY2’s
inhibitory activity, which is mediated by interaction with many signaling proteins including FRS2, SHP2, GRB2, RAF and
PLCδ. On the other hand, its interaction with CBL E3 ubiquitin ligase may positively regulate EGFR signaling, because
such interaction sequesters CBL and prevents CBL-mediated EGFR degradation.
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Upon growth factor stimulation, SPRY2 translocates from the cytosol to the plasma mem‐
brane where it binds to phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] via the con‐
served  SPRY  domain  [73-75].  Membrane  translocation  appears  to  be  triggered  by  the
activated  Rac  small  GTPase  and is  essential  for  SPRY2 function  [76].  The  phosphoryla‐
tion  of  the  Tyr55  residue  in  SPRY2  is  likely  regulated  by  a  SRC  family  kinase,  which
upon  FGF  stimulation  is  recruited  to  activated  FGFR  by  FRS2  [77].  While  Tyr55  phos‐
phorylation enables the binding of SPRY2 to GRB2 via the SH2-binding motif  in the N-
terminus  [78],  the  SH3-binding  motif  in  its  C-terminus  may  also  play  a  role  in  the
SPRY2-GRB2 interaction [39-41] (Figure 1B).  The latter is  likely regulated by the protein
phosphatase 2A (PP2A), a serine/threonine phosphatase that interacts with Tyr55 and de‐
phosphorylates  certain  serine  residues  in  SPRY2  for  permitting  access  of  GRB2  to  the
SH3-binding motif on SPRY2 [41, 45]. Consequently, the binding of SPRY2 to GRB2 pre‐
vents the recruitment of the GRB2-SOS complex to the FRS2 adaptor or SHP2 phospha‐
tase  proximal  to  the  activated  RTK,  thereby  inhibiting  the  activation  of  RAS  and  its
downstream molecules [10,  36,  39,  77,  78].  The RTK-RAS-RAF-MAPK/ERK pathway can
also  be  inhibited  by  direct  binding  of  SPRY2  to  RAF  [75,  79,  80].  On  the  other  hand,
TESK1 negatively  regulates  SPRY2 inhibitory  activity  by interfering with  the  SPRY2 in‐
teraction with GRB2 and PP2A [81], while DYRK1A binding results in Thr75 phosphory‐
lation  on SPRY2 and suppression of  SPRY2 inhibitory  activity,  thereby enhancing FGF-
induced ERK activation [42].
The regulation of EGFR signaling by SPRY2 appears to be more complicated than that of
FGFR signaling, because SPRY2 can indirectly influence the turnover of EGFR through its
interaction with CBL (Figure 3) [10, 36, 37]. This regulation is mediated by the SH2-binding
motif, which includes Tyr55 in the N-terminus of SPRY2. When Tyr55 is phosphorylated,
SPRY2 interacts with the SH2-domain on CBL, and prevents CBL from binding to the acti‐
vated EGFR, thereby interfering with CBL-mediated EGFR endocytosis and degradation [43,
82-84]. This action can prolong the activation of EGFR and the downstream RAS-RAF-
MAPK pathway, contrary to the direct inhibitory activity of SPRY2 on the downstream sig‐
naling molecules. These two opposite activities render SPRY2 a delicate role in fine-tuning
EGFR signaling, negative in some situations and positive in others, depending on the
threshold and balance of these two activities.
It is conceivable that RTKs such as MET and PDGFR that are also substrates of CBL might
also be affected by SPRY2 like that of EGFR [8, 85], while non-CBL-substrate RTKs like
FGFR appears unaffected by SPRY2-CBL interaction [36]. However, it is known that MET
protein level is not affected by SPRY2 overexpression that inhibits HGF-induced ERK and
AKT activation, indicating that the effect of SPRY2-CBL interaction on EGFR and on MET
might not be the same [72, 86]. The sequestration of CBL by SPRY2 can also affect down‐
stream signaling molecules, as it may free proteins like GRB2 from CBL-mediated ubiquiti‐
nation and degradation [85]. Furthermore, SPRY2 itself can be ubiquitinylated and degraded
by the CBL binding, thereby influencing the RTK signaling [83].
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4. Tumor suppressor role of MIG-6 and SPRY2 in cancer
4.1. MIG-6 as a tumor suppressor gene
Human  chromosome  1p36,  a  locus  frequently  associated  with  many  human  cancers
[87-92],  harbors the MIG-6  gene. In fact,  loss or reduction of MIG-6  expression has been
observed  in  non-small  cell  lung  cancer  (NSCLC)  [35,  93-95],  breast  carcinoma  [30,  96],
melanoma and skin cancer [30, 94], ovarian carcinoma [30], pancreatic cancer [30], endo‐
metrial cancer [34], thyroid cancer [97, 98], hepatocellular carcinoma [28], and glioblasto‐
ma [91]. Prognostically, low MIG-6  expression is often associated with poor prognosis or
poor patient survival [93, 96, 97].
Unlike many other tumor suppressor genes whose expression is directly regulated by epige‐
netic modification of their promoter regulatory elements [3], the silencing of MIG-6 expres‐
sion seems otherwise [94]. Although high in CpG contents, the MIG-6 promoter appears
hypomethylated and is not directly affected by either the DNA methyltransferase inhibitor
5-aza-2’-deoxycytidine [5-aza-dC) or the histone deacetylase inhibitor trichostatin A (TSA),
indicating indirect regulation [94]. Interestingly, MIG-6 expression seems to be differently
induced by 5-aza-dC and TSA in different cancer types: it is induced by 5-aza-dC in melano‐
ma but not in NSCLC and neuroblastoma, and by TSA in NSCLC and neuroblastoma but
not in melanoma, suggesting a possible tissue-specific transcriptional regulation for this
gene [90, 94, 96]. However in some papillary thyroid cancer, it is reported that the MIG-6
promoter is hypermethylated as determined by methylation-specific PCR [98]. It is unclear
at this point what cause such differences.
Besides loss or reduction of expression, MIG-6 can also be inactivated by genetic mutation,
even though this occurs rarely [35, 90, 96]. To date, two homozygous mutations (Asp109 to
Asn, and Glu83 to a stop codon) in MIG-6 were identified in human lung cancer cell lines,
while heterozygous germline mutations were found in a primary lung cancer (Ala373 to
Val) and a neuroblastoma patient (Asn343 to Ser) [35, 90]. Evidence that MIG-6 is a bona fide
tumor suppressor gene also arises from mouse studies. Mice with targeted disruption of
Mig-6 are prone to neoplastic development ranging from epithelial hyperplasia to carcinoma
at multiple sites including the lung, gallbladder, bile duct, uterus, gastrointestinal tract and
skin [30, 34, 35]. The carcinogen-induced skin cancer seen in Mig-6-deficient mice is likely
mediated by EGFR-ERK/MAPK pathway, because inhibiting EGFR kinase activity with gefi‐
tinib or replacing it with a kinase-defective EGFR rescues the phenotype [30].
4.2. SPRY2 as a tumor suppressor gene
There is compelling evidence supporting SPRY2 as a tumor suppressor [99]. The SPRY2
gene is located on human chromosome 13q31, where loss of heterozygosity (LOH) is ob‐
served in prostate cancer and hepatocellular carcinoma [86, 100]. Down-regulation of SPRY2
expression has been reported in breast cancer [55, 101], hepatocellular carcinoma [86, 102,
103], NSCLC [104], prostate cancer [100, 105, 106], endometrial carcinoma [107], gliomas
[108], and B-cell lymphomas [109, 110]. However in colon cancer, both downregulation and
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upregulation of SPRY2 have been reported [111, 112]. Low (or no) SPRY2 expression is asso‐
ciated with advanced tumor stages and poor survival, and it may be a significant prognostic
factor in breast cancer [101], hepatocellular carcinoma [86, 103], prostate cancer [100, 105],
gliomas [108], and colon cancer [111]. Further, SPRY2 expression is inversely correlated with
the level of miR-21 microRNA expression in gliomas and colon cancer, indicating that
SPRY2 is a target of miR-21[108, 111].
Downregulation of SPRY2 expression may be attributed to DNA methylation; hypermethy‐
lation of its promoter has been observed in prostate cancer [100], hepatocellular carcinoma
[86], endometrial carcinoma [107] and B-cell lymphomas [109, 110]. However, controversial
results have also been reported, since no methylation in SPRY2 promoter was found in other
studies involving different cancer types [55, 102, 106, 111], indicating that other epigenetic
mechanisms might as well be responsible for SPRY2 down-regulation. Thus far, no mutation
has been identified in the SPRY2 gene in any human cancers, and no neoplastic phenotypes
have been observed in any Spry2-deficient mice. This may be due to compensatory roles
played by other family members such as SPRY1 or SPRY4.
5. The impacts of MIG-6 or SPRY2 activity on RTK signaling in cancer
The loss of MIG-6 and SPRY2 feedback regulation leads to prolonged RTK signaling activa‐
tion and may contribute to hallmark activities of cancer [113]. Ectopic expression of MIG-6
results in decreased phosphorylation of EGFR/ErbBs and downstream ERK/MAPK and
AKT, and it inhibits cell proliferation in several cancer types [19, 20, 65, 96, 114]. In contrast,
down-regulation of MIG-6 expression by small interference RNA (siRNA)-mediated knock‐
down leads to prolonged activation of the EGFR or ErbB2 pathway and increases ligand-in‐
duced proliferation, cell cycle progression, and cell migration [28, 30, 65, 96, 114]. Likewise,
MIG-6 overexpression inhibits HGF-induced cell migration and proliferation, whereas
MIG-6 knockdown by siRNA enhances those activities [14]. Intriguingly, it has been shown
that in thyroid cancer, MIG-6 overexpression suppresses MET phosphorylation along with
the inhibition of EGFR, ErbB2, and SRC, while its knockdown does the opposite and enhan‐
ces cell proliferation and invasion [98]. However, it is unclear how MIG-6 affects MET tyro‐
sine phosphorylation given that no physical interaction between the two is observed [14].
The activity of MIG-6 on apoptosis is unsettled: one group showed that MIG-6 inhibits
apoptosis of breast cancer cells [115], while another showed that it promotes the death of
cardiomyocytes [25]. This discrepancy might be due to the differences in cellular states (can‐
cer cells versus normal cells) or in tissue types (breast versus cardiac).
Nonetheless, a study of NCI-60 cell lines, which cover a broad spectrum of cancer types, re‐
vealed that MIG-6 expression correlated with EGFR expression, indicating an intrinsic activ‐
ity for MIG-6 in regulating EGFR signaling [116]. MIG-6 expression has been shown to have
a significant effect on ErbB-targeted cancer therapy [96, 116, 117]. MIG-6 synergizes with the
EGFR inhibitor gefitinib to suppress the growth of NSCLC cells carrying gefitinib-sensitive
EGFR mutations [116, 117]. Further, the loss of MIG-6 expression renders ErbB2-amplified
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breast cancer cells more resistant to Herceptin (trastuzumab), a neutralizing antibody
against ErbB2/HER2 [96]. It will be interesting to see the influence of MIG-6 expression on
cancer therapies targeting other RTKs such as MET as well.
SPRY2  overexpression inhibits MET-mediated ERK and AKT activation in leiomyosarco‐
ma and hepatocellular carcinoma cells, and it suppresses cell proliferation, migration and
invasion induced by HGF [72, 86, 102].  In NSCLC, SPRY2 suppresses ERK but not AKT
activation, and it inhibits the migration of the cells expressing wild-type but not constitu‐
tively  activated  K-RAS;  however,  proliferation  and  tumorigenesis  of  cells  with  either
wild-type or mutant K-RAS can be inhibited by SPRY2  overexpression [104].  SPRY2 has
different effects on wild-type and V599E mutant B-RAF in melanoma cells: its downregu‐
lation enhances ERK phosphorylation only in melanoma cells carrying wild-type B-RAF,
likely  because  of  its  ability  to  interact  with  wild-type,  but  not  mutant,  B-RAF  [118].
Overexpression of SPRY2  suppresses ERK activation in osteosarcoma and B-cell lympho‐
ma, and it  inhibits tumor growth and metastasis in vivo  [109, 119],  while suppression of
SPRY2 activity by its dominant negative mutant SPRY2Y55F enhances the proliferation and
tumorigenesis  of  breast  cancer  cells  [55].  Surprisingly,  SPRY2 has  also  been reported to
enhance cell  proliferation and HGF-induced ERK and AKT activation, migration and in‐
vasion of  colon cancer  cells  [112],  quite  opposite  to  another  report  showing that  in  the
same cell  line,  SPRY2 negatively  regulates  ERK and AKT phosphorylation  and inhibits
proliferation,  migration and tumorigenesis  [111].  The discrepancy is  quite  puzzling,  and
it  is  unclear whether it  is  due to differences in the experimental  approaches or to other
factors such as clonal effects originating from tumor cell heterogeneity. Using an induci‐
ble system in the same cell line might be able to solve the puzzle of whether the effects
in those two reports were truly the results of SPRY2 overexpression.
There is limited evidence that SPRY2 expression, like that of MIG-6, influences ErbB-target‐
ed therapy in human cancers [101, 120]. Breast cancer patients with low SPRY2 expression
show poorer response to trastuzumab treatment, and have a significant lower survival rate
relative to those with high SPRY2 expression [101]. Low SPRY2 expression is usually associ‐
ated with high ErbB2/HER2 in breast cancer, while reconstituting SPRY2 may enhance the
sensitivity of breast cancer cells in vitro to trastuzumab treatment [101]. In colon cancer cells,
low SPRY2 expression is associated with less sensitivity to gefitinib, whereas its ectopic
overexpression can enhance gefitinib responsiveness [120].
6. Conclusion and perspective
The negative feedback loops to receptor tyrosine kinases of MIG-6 and of SPRY2 provide
crucial  intersecting  points  for  tumor  suppressor  genes  and  oncogenes,  placing  them  in
the same signaling networks  for  regulating physiologic  and oncogenic  activity.  This  so‐
phisticated  regulatory  mechanism  allows  timely  attenuation  of  RTK  signaling  by  those
TSGs, and ensures a proper cellular response following growth factor stimulation. MIG-6
and SPRY2 are no more than the representatives for the class of TSGs involved in RTK
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signaling regulation, and we believe there are more such TSGs in the human genome ei‐
ther remain to be discovered or have already been revealed (such as other SPRY family
members).  To date,  most of  the studies on MIG-6 and SPRY2 have focused on their  ac‐
tivity in regulating selected RTKs such as EGFR, MET and FGFR. Their roles in regulat‐
ing  most  other  RTKs  and  the  clinical  relevance  of  such  regulation  remain  largely
unknown. Also, there are conflicting results on how MIG-6 and SPRY2 may regulate the
RTK  signaling,  on  both  the  receptor  and  the  downstream  signaling  levels,  and  further
studies are required to address those issues.  Although EGFR and other  RTKs like MET
appear to be regulated slightly differently by MIG-6 and SPRY2, it  remains to be deter‐
mined to what extent these TSGs may provide signaling specificity to different RTKs. Be‐
yond all aforementioned issues, a broader question might be why an RTK network needs
multiple  negative  feedback  regulators  to  fine-tune  its  signaling;  might  the  regulators
function differently for each RTK in a temporal and spatial manner i.e. at right place, on
right time and for right target?
While conventional mechanisms such as mutation or promoter methylation may contribute
to the inactivation of MIG-6 or SPRY2 tumor suppressor roles, their activities are also likely
silenced by unconventional means in cancer. For example, in most cancer types investigated
so far, MIG-6 expression is not down-regulated by direct methylation or histone deacetyla‐
tion in its promoter, but rather by an indirect mechanism involving other unidentified tran‐
scriptional factor(s) or transcriptional co-regulator(s). It is also striking to see that different
promoter methylation status in MIG-6 or SPRY2 gene is observed in different cancer types:
methylated in some cancers, but unmethylated in others. The cause of such difference is a
curiosity, but if only for TSG down-modulation, genome instability in the cancer cell envi‐
ronment could provide many mechanisms.
Clinically, it is important to understand how tumor suppressor genes may affect the thera‐
peutic outcome of RTK-targeted therapies, which can be effective in treating certain human
cancers. In a limited number of studies, low expression of MIG-6 or SPRY2 is associated
with poorer patient responses to ErbB-targeted therapies (i.e., the EGFR inhibitor gefitinib
and the ErbB2/HER2 inhibitor Herceptin). The question is, can MIG-6 or SPRY2 expression
be used in conjunction with RTK status to select patients for RTK-targeted “personalized”
cancer therapy? The approach sounds plausible, given that those TSGs negatively regulate
the RTK signaling activities, but extensive studies will certainly be required before imple‐
menting such measures.
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